-
-
-
-
-
-
-
AstraZeneca (AZN) PT Raised to $109 at Morgan Stanley
-
-
-
-
-
-
-
AstraZeneca is set to report on Tuesday. Here's what to watch out for.
-
-
-
-
-
-
-
AstraZeneca beats forecasts in Q3, reaffirms full-year guidance
-
-
-
-
-
-
-
UBS identifies stock winners amid structural growth tailwinds
-
-
-
-
-
-
-
AstraZeneca breast cancer drug shows positive results, shares up
-
-
-
-
-
-
-
AstraZeneca (AZN) Reports CALQUENCE plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
-
-
-
-
-
-
-
AstraZeneca’s 9M and Q3 2024 results
-
1,204,702 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

